Bacil Pharma Ltd Approves Rights Issue and Capital Increase; Independent Directors Resign

Bacil Pharma Ltd Approves Rights Issue and Capital Increase; Independent Directors Resign​

Bacil Pharma Limited announced several significant outcomes from its Board of Directors meeting held on July 9, 2026, approving plans for capital augmentation while also confirming changes to its board composition.

The Board approved a proposal to raise funds through a Rights Issue of equity shares amounting up to ₹50,00,00,000 (Rupees Fifty Crores Only). Simultaneously, the company approved an increase in its Authorized Share Capital by an additional ₹45,00,00,000 (Rupees Forty-Five Crores Only).

This capital expansion involves issuing 4,50,00,000 Equity Shares of Rs. 10/- each face value. Following the approval of this increase, the company’s post-increase authorized capital will stand at ₹65,00,00,000 (Rupees Sixty-Five Crores Only).

Key operational details and corporate structure changes approved by the Board include:

• Intermediaries for Rights Issue: The board formally took on record the appointments of M/s Purva Sharegistry (India) Private Limited as Registrar for the Right Issue, Axis Bank Limited (Sakinaka Branch) as Banker to the Issue, and Acuite Ratings & Research Limited as the Monitoring Agency.
• Authorization: Ms. Chaitali Kalpataru Shah (Executive Director & CFO), along with the Company Secretary, was authorized by the Board to handle all necessary applications, deeds, agreements, and documents pertaining to the approved Right Issue proposal.

Governance Changes and Committee Formation​

The meeting also addressed changes in the company's board composition. The Board unanimously approved the resignation of Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya from their respective roles as Independent Directors.

In a related move, the Board of Directors formed a Right Issue Committee consisting of:

• Chaitali Kalpataru Shah (Executive Director & CFO) as Chairman.
• Vivek Mukesh Yadav (Independent Director) as Member.
• Omprakash Pyarelal Sonar (Independent Director) as Member.

The company has also maintained that the Trading Window for dealing in its securities shall remain closed for all designated persons and their immediate relatives until 48 hours following the declaration of the outcome of the Board Meeting.

Stock Price Movement​

Bacil Pharma Ltd shares settled at ₹38.50 in the post-market session, edging higher after closing up 0.36%. The stock navigated a volatile day, trading between an intraday low of ₹37.26 and a high of ₹39.89.